Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

BackgroundSerum protein profiles have been investigated frequently to discover early biomarkers for breast cancer. So far, these studies used biological samples collected at or after diagnosis. This may limit these studies' value in the search for cancer biomarkers because of the often advanced tumor stage, and consequently risk of reverse causality. We present for the first time pre-diagnostic serum protein profiles in relation to breast cancer, using the Prospect-EPIC (European Prospective Investigation into Cancer and nutrition) cohort.MethodsIn a nested case-control design we compared 68 women diagnosed with breast cancer within three years after enrollment, with 68 matched controls for differences in serum protein profiles. All samples were analyzed with SELDI-TOF MS (surface enhanced laser desorption/ionization time-of-flight mass spectrometry). In a subset of 20 case-control pairs, the serum proteome was identified and relatively quantified using isobaric Tags for Relative and Absolute Quantification (iTRAQ) and online two-dimensional nano-liquid chromatography coupled with tandem MS (2D-nanoLC-MS/MS).ResultsTwo SELDI-TOF MS peaks with m/z 3323 and 8939, which probably represent doubly charged apolipoprotein C-I and C3a des-arginine anaphylatoxin (C3adesArg), were higher in pre-diagnostic breast cancer serum (p = 0.02 and p = 0.06, respectively). With 2D-nanoLC-MS/MS, afamin, apolipoprotein E and isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 (ITIH4) were found to be higher in pre-diagnostic breast cancer (p < 0.05), while alpha-2-macroglobulin and ceruloplasmin were lower (p < 0.05). C3adesArg and ITIH4 have previously been related to the presence of symptomatic and/or mammographically detectable breast cancer.ConclusionsWe show that serum protein profiles are already altered up to three years before breast cancer detection.

[1]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[2]  Jos H Beijnen,et al.  Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. , 2006, World journal of gastroenterology.

[3]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[4]  Jacob Kennedy,et al.  Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. , 2010, Cancer research.

[5]  J. Barrett,et al.  Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. , 2005, Clinical chemistry.

[6]  Jiekai Yu,et al.  SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. , 2005, Breast.

[7]  S. Hanash,et al.  Confounding Effects of Hormone Replacement Therapy in Protein Biomarker Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[8]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[9]  S. Lorda,et al.  A systematic review of the effectiveness of magnetic resonance imaging ( MRI ) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer , 2007 .

[10]  Sen-Yung Hsieh,et al.  Systematical evaluation of the effects of sample collection procedures on low‐molecular‐weight serum/plasma proteome profiling , 2006, Proteomics.

[11]  E. Marchiori,et al.  Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.

[12]  Marie-Christine W. Gast,et al.  Serum degradome markers for the detection of breast cancer. , 2010, Journal of proteome research.

[13]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[14]  N Slimani,et al.  Estimation of reproducibility and relative validity of the questions included in the EPIC Physical Activity Questionnaire. , 1997, International journal of epidemiology.

[15]  Z. Hall.  Cancer , 1906, The Hospital.

[16]  Charles Darwin,et al.  Experiments , 1800, The Medical and physical journal.

[17]  F. Bertucci,et al.  Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy , 2006, Oncogene.

[18]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[19]  Milos Hauskrecht,et al.  Intersession reproducibility of mass spectrometry profiles and its effect on accuracy of multivariate classification models , 2007, Bioinform..

[20]  J. Schellens,et al.  Influence of variations in sample handling on SELDI‐TOF MS serum protein profiles for colorectal cancer , 2008, Proteomics. Clinical applications.

[21]  A. Vlahou,et al.  A novel approach toward development of a rapid blood test for breast cancer. , 2003, Clinical breast cancer.

[22]  Jeffrey S. Morris,et al.  The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. , 2005, Briefings in functional genomics & proteomics.

[23]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[24]  Hyo-Jin Yoon,et al.  Sensitivity enhancement of a dynamic mode microcantilever by stress inducer and mass inducer to detect PSA at low picogram levels. , 2009, Lab on a chip.

[25]  Marie-Christine W. Gast,et al.  SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. , 2006, Cancer biomarkers : section A of Disease markers.

[26]  Carole Mathelin,et al.  Serum biomarkers for detection of breast cancers: a prospective study , 2006, Breast Cancer Research and Treatment.

[27]  Xiao-Ying Meng,et al.  Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. , 2005, Clinical chemistry.

[28]  R. Poisson,et al.  Biologic markers and breast cancer: a multiparametric study--1. Increased serum protein levels. , 1981, Cancer.

[29]  E. Riboli,et al.  Prospect-EPIC Utrecht: Study design and characteristics of the cohort population , 2004, European Journal of Epidemiology.

[30]  Lori J Sokoll,et al.  Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. , 2006, Clinical chemistry.

[31]  Marie-Christine W. Gast,et al.  Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) , 2009, Clinical chemistry and laboratory medicine.

[32]  P. Tempst,et al.  Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.

[33]  Zhiyuan Luo,et al.  Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. , 2007, Clinical chemistry.

[34]  D. Grobbee,et al.  Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study , 2009, BMC Medical Genomics.

[35]  Marie-Christine W. Gast,et al.  Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. , 2009, Oncology reports.

[36]  T. Veenstra,et al.  Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. , 2005, Clinical chemistry.

[37]  Emanuel F. Petricoin,et al.  Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer , 2007, Annals of Surgical Oncology.

[38]  E. Birney,et al.  The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.